Remgro should know better. If the JSE’s largest investment company is serious about restructuring its portfolio to close a frustrating market discount, then perhaps it should not be pitching opportunistic buyout offers to minority shareholders in Mediclinic International.

But if a deal eventually does come off, Remgro will be taking a huge step towards reinventing itself as a compelling hub of top-quality unlisted investments...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.